共 64 条
[1]
Coleman R.E.(2006)Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 6243s-6249s
[2]
Mundy G.R.(2002)Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 584-593
[3]
Coleman R.E.(2001)Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165-176
[4]
Ulrich U.(2001)Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer Arch Gynecol Obstet 264 186-190
[5]
Rhiem K.(2001)Use of markers of bone turnover for monitoring bone metastases and the response to therapy Semin Oncol 28 54-59
[6]
Schmolling J.(1991)Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis J Bone Miner Res 6 639-644
[7]
Lipton A.(2006)The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc Natl Acad Sci U S A 103 7829-7834
[8]
Costa L.(2002)Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa) J Med Chem 45 3721-3738
[9]
Ali S.(2005)Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC) J Orthop Res 23 1004-1012
[10]
Delmas P.D.(2003)Antitumor effects of bisphosphonates Cancer 97 840-847